Evaluation of Efficacy and Safety of Drug Combination in Patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD)

The primary objective of the study titled "ERASE PH-COPD" is to evaluate the efficacy of a treatment in patients with **Pulmonary Hypertension**. This condition is characterized by elevated blood pressure in the pulmonary arteries, which can lead to significant morbidity and mortality. Understanding the impact of the treatment on this condition is clinically relevant as it may offer insights into improving patient outcomes and quality of life. No secondary objectives are provided for this study.

The clinical trial focuses on participants diagnosed with **Pulmonary Hypertension**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically encompass adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed by the sponsor. Key inclusion or exclusion criteria have not been disclosed.

The clinical trial is designed to evaluate interventions for **Pulmonary Hypertension**. The study follows a randomized, double-blind, controlled trial design, ensuring that neither the participants nor the researchers know which treatment the participants are receiving, thus minimizing bias. The trial is set to commence recruitment on February 1, 2023, and is estimated to conclude by July 31, 2023, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. This initial visit is crucial for determining eligibility based on predefined criteria. Following successful inclusion, participants will attend scheduled follow-up visits, which are essential for monitoring the treatment's efficacy and safety. These visits will include assessments and data collection as per the trial protocol. The end-of-study visit marks the conclusion of the participant's involvement, where final evaluations and data collection will occur.

The expected duration of participant involvement spans the entire trial period, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied, the trial's main objective, or any other pertinent details that would typically be included in a clinical trial description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 5, indicating a focus on post-marketing surveillance to gather additional information on the drug's effectiveness and safety. The trial is scheduled to commence recruitment on February 1, 2023, with an estimated end date of July 31, 2023. Efficacy assessments will be conducted at predetermined intervals throughout the trial duration. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and tools for measurement, are not detailed in the provided data. The trial will adhere to rigorous standards to ensure the collection and analysis of efficacy data are conducted with scientific precision.